Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Enhancing Japan's Presence in Multinational Clinical Trials
February 23, 2009
- REGULATORY NEWS IN BRIEF
February 23, 2009
- PMDA Announces Draft of 2nd Mid-Term Plan
February 23, 2009
- FDA Approves Gout Treatment from Teijin/Takeda
February 23, 2009
- BUSINESS NEWS IN BRIEF
February 23, 2009
- 3-Qtr Business Results: 3
February 23, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 23, 2009
- Olmetec Goes to Front on Both GP and HP Markets: Rep Track Survey
February 23, 2009
- Deposit Sales System Discussed by Council Members
February 23, 2009
- Meiji Seika to Develop Antibody Drugs for Infectious Diseases in Earnest
February 23, 2009
- 3-Track System to Be Introduced to Eliminate "Device Lag"
February 23, 2009
- MTPC Continues Cost-cutting Efforts
February 23, 2009
- The 12 Steps to Marketing Success
February 23, 2009
- Astellas to Reinforce Its Global Development System
February 23, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 23, 2009
- Five Factors Responsible for Drug Lag: Mr Sekiguchi
February 23, 2009
- SSP: Hythiol-C Struggles due to Tougher Competition
February 23, 2009
- Novartis Gears Up to Enter the Top Three in Japan
February 23, 2009
- Pharmacists Are Consumers' Final Line of Defense
February 23, 2009
- GENERICS NEWS IN BRIEF
February 23, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…